Work

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.009

Authors: D.J. McGrail, P.G. Pilié, N.U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, A.B. Heimberger, N.T. Ueno, R. Ferrarotto, J.T. Chang, S.-Y. Lin

Institutions: Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The Netherlands Cancer Institute, Oncode Institute, Duke University, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas Health Science Center at Houston

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, Celldex Therapeutics, Ipsen, National Institutes of Health, National Cancer Institute, Daiichi Sankyo Europe

Award: G510513728

OpenAlex ID: W4289260268

FWCI: 0.722

Cites: 9

Cited by: 8

Related to: 10